Key Points Wegovy patients lost an average of 16% of their body weight against 2% for placebo users in clinical trials. Zepbound patients lost 20.9% body weight and up to 26% after 88 weeks compared to 9.5% for the placebo group, but dosages rose to 15 mg a week versus 2.4 mg for Wegovy. Both drugs are being researched for additional indications, including cardiovascular, MASH and neurological diseases. 5 stocks we like better than Novo Nordisk A/S The GLP-1 weight loss trend continues to flourish, and the ...